Funds advised by global private equity advisory firm Apax are set to acquire ophthalmic lens manufacturer Rodenstock Group in a deal reported to be worth AU$2.3 billion. Read more
European Commission clears EssilorLuxottica’s GrandVision takeover, 350 stores to be divested
The European competition watchdog has cleared EssilorLuxottica’s acquisition of Europe’s largest retail optical chain GrandVision, on the condition that around 350 stores are divested across three countries. Read more
Aussie study uncovers genetic cause of MacTel
Melbourne researchers have identified an additional seven regions in the human genome that increase the risk of macular telangiectasia type 2 (MacTel), with one particular mutation raising the likelihood of the condition five-fold. Read more
Safilo introducing two new sustainable materials from 2022
Safilo has announced it will begin incorporating two new sustainable materials containing recycled content into its eyewear collections, beginning with its proprietary brand Polaroid. Read more
Oculo acquired by Finnish ophthalmic device company
Australian-owned teleophthalmology and clinical communication platform Oculo will change hands in the coming months following an announcement this week that Finnish ophthalmic diagnostics company Revenio has purchased the platform. Read more
Opthea treats first patient in Phase 3 nAMD trial
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular degeneration (nAMD) has been treated in the US. Read more
EyeQ and NOC announce executive reshuffle
A new alliance between Australian optometry groups National Optical Care (NOC) and EyeQ Optometrists has sparked personnel changes involving the CEOs of both entities. Read more
Close the Gap Day: RANZCO commits to more Indigenous ophthalmologists
As Australia marks National Close the Gap Day, RANZCO has reaffirmed its commitment to increasing the number of Aboriginal and Torres Strait Islander ophthalmologists. Read more
’90 seconds without blinking’ – Sydney ophthalmologists repurpose cholesterol drug into dry eye therapy
Two Australian ophthalmologists are repurposing a common cholesterol-lowering drug into a topical ocular therapy for dry eye and blepharitis, which was given to a patient as part of an initial trial who went 90 seconds without blinking.
New ProVision business resource helps independents build a thriving team
ProVision’s recently launched resource for budding independent practice owners features a new module to help businesses build their “dream team” and workplace culture. Read more